GlassScriptPhysician profile
Michael Angelis
NPI 1770577504
$2,479.82
in general payments reported to CMS, 2019-2025
17 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $211 · 2021: $158 · 2022: $91.01 · 2023: $86.49 · 2024: $1,594 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,564 · Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,563.81 |
| Food and Beverage | $239.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Transmedics, INC. | $1,563.81 | 2024 | Organ Care System |
| Intercept Pharmaceuticals, INC. | $161.19 | 2020-2023 | Ocaliva |
| Integra Lifesciences Corporation | $149.32 | 2019-2025 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Hakim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.93 | 2019-2025 | Xifaxan |
| Ethicon US, LLC | $105.70 | 2019-2022 | |
| Shionogi INC | $65.02 | 2019-2022 | |
| Veloxis Pharmaceuticals, INC. | $51.84 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $48.45 | 2020-2023 | Flumist Quadrivalent |
| Gilead Sciences, INC. | $38.45 | 2020-2021 | |
| Vifor Pharma, INC. | $37.87 | 2021 | |
| Abbott Laboratories | $22.27 | 2021 | |
| Azurity Pharmaceuticals, INC. | $21.70 | 2025 | Katerzia |
| E.R. Squibb & Sons, L.L.C. | $18.68 | 2020 | |
| Allergan, INC. | $14.81 | 2020 | |
| Merck Sharp & Dohme LLC | $13.65 | 2023 | Dificid, Zerbaxa, Prevymis |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $12.98 | 2020 | |
| Vivus LLC | $9.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Angelis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.